Skip to main content
Log in

Recombinant interferon alpha (rIFNα-2b) may retard progression of early primary myelofibrosis

  • Letter to the Editor
  • Published:
Leukemia Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Figure 1
Figure 2
Figure 3

References

  1. Kiladjian J-J, Chomienne C, Fenaux P . Interferon-α therapy in bcr-abl-negative myeloproliferative neoplasms. Leukemia 2008; 22: 1990–1998.

    Article  CAS  PubMed  Google Scholar 

  2. Chott A, Gisslinger H, Thiele J, Fritz E, Linkesch W . Interferon-alpha induced morphological changes of megakaryocytes: a histomorphological study on bone marrow biopsies in chronic myeloproliferative disorders with excess thrombocytoses. Br J Hematol 1990; 74: 10–16.

    Article  CAS  Google Scholar 

  3. Wang Q, Miyakawa Y, Fox N, Kaushansky K . Interferon-alpha directly represses megakaryopoiesis by inhibiting thrombopoietin-induced signaling through induction of SOCS-1. Blood 2000; 96: 2093–2099.

    CAS  PubMed  Google Scholar 

  4. Yamane A, Nakamura T, Suzuki H, Ito M, Ohnishi Y, Ikeda Y et al. Interferon-alpha 2b-induced thrombocytopenia is caused by inhibition of platelet production but not proliferation and endomitosis in human megakaryocytes. Blood 2008; 112: 542–550.

    Article  CAS  PubMed  Google Scholar 

  5. Barosi G, Bordessoule D, Briere J, Cervantes F, Demory J-L, Dupriez B et al. Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myelofibrosis Network (EUMNET). Blood 2005; 106: 2849–2853.

    Article  CAS  PubMed  Google Scholar 

  6. Manoharan A, Horsley R, Pitney WR . The reticulin content of bone marrow in acute leukaemia in adults. Br J Haematol 1979; 43: 185–190.

    Article  CAS  PubMed  Google Scholar 

  7. Silver RT . Long-term effects of the treatment of polycythemia vera with recombinant interferon-α. Cancer 2006; 107: 451–458.

    Article  CAS  PubMed  Google Scholar 

  8. Dupriez B, Morel P, Demory JL, Lai JL, Simon M, Plantier I et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood 1996; 88: 1013–1018.

    CAS  PubMed  Google Scholar 

  9. Tefferi A . The history of myeloproliferative disorders: before and after Damashek. Leukemia 2008; 22: 3–13.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by a grant form the William and Judy Higgins Trust of the Cancer Research and Treatment Fund, Inc., New York, NY, USA.

We acknowledge the measurement of JAK2V617F allele burden by Dr Lynn Wang, Dr Nicholas CP Cross and Amy Jones. Drs Attilio Orazi, Wayne Tam and Amy Chadburn independently reviewed marrow biopsies for this study. Paul Christos provided statistical assistance.The Weill Cornell Medical College Institutional Review Board has approved this retrospective review of patients treated with interferon. Presented in part at the 50th Annual Meeting of the American Society of Hematology, 6–9 December, 2008, San Francisco, CA, USA.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to R T Silver.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Silver, R., Vandris, K. Recombinant interferon alpha (rIFNα-2b) may retard progression of early primary myelofibrosis. Leukemia 23, 1366–1369 (2009). https://doi.org/10.1038/leu.2009.90

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2009.90

  • Springer Nature Limited

This article is cited by

Navigation